Based on translational data from the RUBY trial, experts are most cautious about recommending frontline checkpoint inhibitors for patients in the "No Specific Molecular Profile" (NSMP) subgroup of pMMR endometrial cancer, suggesting this group may not benefit.

Potent responses to chemo-immunotherapy are promoting a shift toward neoadjuvant treatment for advanced endometrial cancer. Waiting six cycles often achieves a response sufficient to allow for a minimally invasive hysterectomy instead of a more extensive primary debulking surgery.

As various maintenance therapies (immunotherapy, ADCs) are integrated into endometrial cancer treatment, the next major clinical question is defining how long these agents need to be continued to maximize benefit while minimizing long-term toxicity and patient burden.

While chemo plus immunotherapy showed a benefit in MS-stable patients, it's not curative. The expert predicts clinicians may shift away from using it universally upfront, potentially favoring other agents first for this non-curative but beneficial therapy.

Similar to findings in small cell lung cancer, immunotherapy combinations in advanced ovarian cancer may create a "tail on the curve." Even if median survival benefit is modest, data shows the survival curves remain separated long-term, suggesting a small but significant subset of patients achieves durable survival of 3-5 years.

Even when neoadjuvant immunotherapy achieves an excellent systemic response in MSI-high endometrial cancer, residual disease frequently persists within the uterus. This finding cautions against forgoing hysterectomy based on imaging or systemic response alone.

Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.

Even in elderly or frail patients with MSI-high endometrial cancer, the rapid and effective tumor response from combination chemotherapy and immunotherapy often improves quality of life so significantly that it's the preferred approach over single-agent IO.

Early neoadjuvant trials show that while immunotherapy can eliminate metastatic endometrial cancer, residual disease often persists within the uterus. This suggests the uterus is a protected environment, tempering enthusiasm for omitting hysterectomy even in exceptional responders.